# Doximity shares surge 34% after AI product adoption drives revenue beat and guidance raise

> Doximity shares surged 34% after the company beat Q1 revenue estimates at $156.6 million and raised full-year guidance to $671-681 million, driven by AI product adoption. CEO Jeff Tangney said AI products are unlocking larger commercial opportunities than expected.

- Type: AI news
- Page: https://completeaitraining.com/news/article-on-doximity-ceo-says-ai-is-unlo/
- Published: 2026-08-09
- Updated: 2026-08-10
- Author: Jeroen Erne
- Jobs: Executives and strategy
- Reading time: 2 min

Doximity Inc. (NYSE: DOCS) shares surged 34% on Friday after the company beat fiscal first-quarter revenue estimates and raised its full-year guidance, driven by **AI product adoption** that CEO Jeff Tangney said is opening larger commercial opportunities than expected. The rally was amplified by a short squeeze, with more than 16% of the public float sold short.

Revenue rose 7% year over year to $156.6 million, beating the analyst consensus estimate of $151.7 million. Adjusted EBITDA reached $74.8 million, a 48% margin. Earnings came in at 29 cents per share, slightly below the consensus estimate of 30 cents.

#### AI products drive growth

Tangney said AI Search is helping the company engage with senior executives at pharmaceutical companies and broadening its total addressable market in healthcare. [AI for Executives & Strategy](https://completeaitraining.com/tag/executives-and-strategy/) professionals will find this shift from clinical tools to executive engagement particularly relevant.

"AI is up-leveling our business across the board," Tangney said, adding that the market opportunity unlocked by AI "has been a real surprise and upside for us."

Doximity Ask, the company's clinical AI assistant, was the top-performing U.S.-based model in the NOHARM benchmark, with a 4.8% error rate versus 13.6% for Anthropic's leading model. Tangney said the product achieved the lowest clinical error rates and highest safety ratings among tested U.S.-based models.

Workflow active prescriber growth exceeded 30% year over year, and AI Search queries rose more than 25% sequentially. The company said 165 health system clients now use its AI offerings, a milestone for [AI for Healthcare](https://completeaitraining.com/tag/healthcare/) adoption in clinical settings.

#### CFO signals higher AI spending

CFO Matt Sonefeldt said first-quarter results reflected stronger-than-expected AI adoption by clinicians, prompting Doximity to increase AI investments during fiscal 2027 to support long-term growth opportunities. The company ended the quarter with 127 pharmaceutical and hospital customers generating more than $500,000 in annual subscription revenue on a trailing 12-month basis.

#### Outlook raised

For the fiscal second quarter, Doximity expects revenue of $170 million to $171 million, compared with the analyst consensus estimate of $171.9 million. The company raised its fiscal 2027 revenue guidance to $671 million to $681 million, up from its prior range of $664 million to $676 million and above the consensus estimate of about $670.3 million.

#### Why this matters for executives and strategy

Doximity's results show AI products can directly broaden a company's addressable market and deepen engagement with high-value customers. Tangney said AI Search is helping the company reach senior pharmaceutical executives - a strategic shift that goes beyond the company's traditional clinical user base. For leaders evaluating AI investments, the question isn't just whether AI tools work, but whether they open new **commercial channels** that weren't previously accessible.

---

This is the Markdown form of https://completeaitraining.com/news/article-on-doximity-ceo-says-ai-is-unlo/. The whole site is mapped at https://completeaitraining.com/llms.txt.